• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[한국경제] 국산 CAR-T 항암제, 킴리아 아성 넘는다

2021/08/15

국산 CAR-T 항암제, 킴리아 아성 넘는다 | 한국경제 (hankyung.com)

한국경제 최지원 기자

Prev큐로셀, 국내 최초 CAR-T 임상에서 완전관해 확인
Next큐로셀, 차세대 CD19 CAR-T 국가신약개발사업 임상과제지원 선정
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.